Technical Analysis for CTNM - Contineum Therapeutics, Inc.

Grade Last Price % Change Price Change
F 13.65 2.63% 0.35
CTNM closed up 2.63 percent on Wednesday, November 20, 2024, on approximately normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Down Down

Date Alert Name Type % Chg
Lower Bollinger Band Walk Weakness 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Centerline Cross Bearish 2.63%
New 52 Week Closing Low Bearish 2.63%
Expansion Breakdown Bearish Swing Setup 2.63%
Wide Range Bar Range Expansion 2.63%
New 52 Week Low Weakness 2.63%

   Recent Intraday Alerts

Alert Time
Fell Below Previous Day's Low about 22 hours ago
Down 2 % about 22 hours ago
Down 1% about 22 hours ago
New 52 Week Low about 22 hours ago
60 Minute Opening Range Breakdown 2 days ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Contineum Therapeutics, Inc. Description

Contineum Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation and immunology (NI&I) indications with high unmet need. Contineum is focused on targeting biological pathways associated with specific clinical impairments, that the Company believes, once modulated, can demonstrably impact the course of disease. The Company has a pipeline of internally-developed programs to address multiple NI&I disorders, including PIPE-791, an LPA1 receptor antagonist, in Phase 1 clinical trials for idiopathic pulmonary fibrosis and progressive multiple sclerosis, and PIPE-307, a selective inhibitor of the M1 receptor in a Phase 2 clinical trial for relapse-remitting multiple sclerosis. Contineum is developing PIPE-307 in collaboration with Johnson & Johnson Innovative Medicines.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Disease Neuroscience Inflammation Multiple Sclerosis Idiopathic Pulmonary Fibrosis Small Molecule Therapies

Is CTNM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 21.92
52 Week Low 12.33
Average Volume 82,276
200-Day Moving Average 0.00
50-Day Moving Average 17.45
20-Day Moving Average 17.05
10-Day Moving Average 17.28
Average True Range 1.17
RSI (14) 30.56
ADX 22.75
+DI 15.03
-DI 39.95
Chandelier Exit (Long, 3 ATRs) 16.72
Chandelier Exit (Short, 3 ATRs) 15.85
Upper Bollinger Bands 20.16
Lower Bollinger Band 13.93
Percent B (%b) -0.04
BandWidth 36.60
MACD Line -0.49
MACD Signal Line -0.04
MACD Histogram -0.4505
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.92
Resistance 3 (R3) 15.73 14.78 15.54
Resistance 2 (R2) 14.78 14.21 14.88 15.41
Resistance 1 (R1) 14.22 13.85 14.50 14.41 15.29
Pivot Point 13.27 13.27 13.42 13.37 13.27
Support 1 (S1) 12.71 12.70 12.99 12.90 12.01
Support 2 (S2) 11.76 12.34 11.86 11.89
Support 3 (S3) 11.20 11.76 11.76
Support 4 (S4) 11.39